

Janusz A Jankowski

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8201089/janusz-a-jankowski-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

246
papers

18,871
citations

62
h-index

136
g-index

317
ext. papers

21,139
ext. citations

9.4
avg, IF

5.8
L-index

#	Paper	IF	Citations
246	Multitrait genetic association analysis identifies 50 new risk loci for gastro-oesophageal reflux, seven new loci for Barrett's oesophagus and provides insights into clinical heterogeneity in reflux diagnosis. <i>Gut</i> , 2021 ,	19.2	2
245	Germline variation in the insulin-like growth factor pathway and risk of Barrett's esophagus and esophageal adenocarcinoma. <i>Carcinogenesis</i> , 2021 , 42, 369-377	4.6	4
244	A comprehensive re-assessment of the association between vitamin D and cancer susceptibility using Mendelian randomization. <i>Nature Communications</i> , 2021 , 12, 246	17.4	12
243	Shared Genetic Etiology of Obesity-Related Traits and Barrett's Esophagus/Adenocarcinoma: Insights from Genome-Wide Association Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 427-433	4	4
242	Chemoprevention of Esophageal Cancer 2020 , 113-125		
241	Surgery versus radical endotherapies for early cancer and high-grade dysplasia in Barrett's esophagus. <i>The Cochrane Library</i> , 2020 , 5, CD007334	5.2	1
240	A feasibility trial of Acetic acid-targeted Biopsies versus nontargeted quadrantic biopsies during BARrett's surveillance: the ABBA trial. <i>Endoscopy</i> , 2020 , 52, 29-36	3.4	6
239	Gastroesophageal reflux GWAS identifies risk loci that also associate with subsequent severe esophageal diseases. <i>Nature Communications</i> , 2019 , 10, 4219	17.4	15
238	No Association Between Vitamin D Status and Risk of Barrett's Esophagus or Esophageal Adenocarcinoma: A Mendelian Randomization Study. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2227-2235.e1	6.9	8
237	Genetic variation in is associated with bacteremia secondary to diverse pathogens in African children. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E3601-E3603	11.5	8
236	An assessment of candidate genes to assist prognosis in gastric cancer. <i>Journal of Gastrointestinal Oncology</i> , 2018 , 9, 303-310	2.8	4
235	Development of Quality Indicators for Endoscopic Eradication Therapies in Barrett's Esophagus: The TREAT-BE (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium. <i>American Journal of Gastroenterology</i> , 2017 , 112, 1032-1048	0.7	24
234	Development of quality indicators for endoscopic eradication therapies in Barrett's esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium. <i>Gastrointestinal Endoscopy</i> , 2017 , 86, 1-17.e3	5.2	32
233	Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma. <i>Gut</i> , 2017 , 66, 1739-1747	19.2	24
232	Barrett's Esophagus: Pathogenesis and Prevention 2017 , 11-16		
231	Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis. <i>Lancet Oncology</i> , 2016 , 17, 1363-1373	21.7	94
230	Polymorphism in a lincRNA Associates with a Doubled Risk of Pneumococcal Bacteremia in Kenyan Children. <i>American Journal of Human Genetics</i> , 2016 , 98, 1092-1100	11	30

229	Response to Feuerstein J et al. "Systematic Analysis and Critical Appraisal of the Quality of the Scientific Evidence and Conflicts of Interest in Practice Guidelines (2005-2013) for Barrett's Esophagus". doi:10.1007/s10620-016-4222-2. <i>Digestive Diseases and Sciences</i> , 2016 , 61, 3369-3371	4	
228	BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. <i>American Journal of Gastroenterology</i> , 2015 , 110, 662-82; quiz 683	0.7	92
227	Trefoil Factor Expression in a Human Model of the Early Stages of Barrett's Esophagus. <i>Digestive Diseases and Sciences</i> , 2015 , 60, 1187-94	4	4
226	Estimates of benefits and harms of prophylactic use of aspirin in the general population. <i>Annals of Oncology</i> , 2015 , 26, 47-57	10.3	241
225	Chemoprevention: can we prevent esophageal cancer? 2015 , 199-208		
224	Barrett's Oesophagus Surveillance versus endoscopy at need Study (BOSS): protocol and analysis plan for a multicentre randomized controlled trial. <i>Journal of Medical Screening</i> , 2015 , 22, 158-64	1.4	35
223	Polymorphisms near TBX5 and GDF7 are associated with increased risk for Barrett's esophagus. <i>Gastroenterology</i> , 2015 , 148, 367-78	13.3	76
222	Chemoprevention for Esophageal Carcinoma 2015 , 83-91		
221	Management of Barrett esophagus: a practical guide for clinicians based on the BADCAT and BoB CAT recommendations. <i>Polish Archives of Internal Medicine</i> , 2015 , 125, 765-70	1.9	2
220	British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. <i>Gut</i> , 2014 , 63, 7-42	19.2	863
219	Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. <i>Lancet Oncology</i> , 2014 , 15, 894-904	21.7	213
218	The correlation between reading and mathematics ability at age twelve has a substantial genetic component. <i>Nature Communications</i> , 2014 , 5, 4204	17.4	54
217	Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. <i>Nature Communications</i> , 2014 , 5, 5068	17.4	160
216	Meta-analysis of genome-wide association studies identifies novel loci that influence cupping and the glaucomatous process. <i>Nature Communications</i> , 2014 , 5, 4883	17.4	71
215	The stem cell organisation, and the proliferative and gene expression profile of Barrett's epithelium, replicates pyloric-type gastric glands. <i>Gut</i> , 2014 , 63, 1854-63	19.2	46
214	Genome-wide association analysis identifies 13 new risk loci for schizophrenia. <i>Nature Genetics</i> , 2013 , 45, 1150-9	36.3	1153
213	Tipping the Balance: Benefits and Risks of Aspirin in Chemoprevention of Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2013 , 9, 1-8	1	2
212	Barrett's esophagus: evolutionary insights from genomics. <i>Gastroenterology</i> , 2013 , 144, 667-9	13.3	4

211	Common variants in the HLA-DRB1-HLA-DQA1 HLA class II region are associated with susceptibility to visceral leishmaniasis. <i>Nature Genetics</i> , 2013 , 45, 208-13	36.3	76
210	Identification of lineage-uncommitted, long-lived, label-retaining cells in healthy human esophagus and stomach, and in metaplastic esophagus. <i>Gastroenterology</i> , 2013 , 144, 761-70	13.3	46
209	Genome-wide meta-analyses of multiancestry cohorts identify multiple new susceptibility loci for refractive error and myopia. <i>Nature Genetics</i> , 2013 , 45, 314-8	36.3	314
208	Genome-wide association study of intraocular pressure identifies the GLCCI1/ICA1 region as a glaucoma susceptibility locus. <i>Human Molecular Genetics</i> , 2013 , 22, 4653-60	5.6	24
207	OC-030 Barrett's Epithelium Shows Evidence of Gastric and Intestinal Differentiation Programmes but Preserves the Proliferative and Stem Cell Architecture of Gastric Glands. <i>Gut</i> , 2013 , 62, A13.2-A13	19.2	
206	Comparing virtual with conventional microscopy for the consensus diagnosis of Barrett's neoplasia in the AspECT Barrett's chemoprevention trial pathology audit. <i>Histopathology</i> , 2012 , 61, 795-800	7.3	17
205	Surgery versus radical endotherapies for early cancer and high-grade dysplasia in Barrett's oesophagus. <i>The Cochrane Library</i> , 2012 , 11, CD007334	5.2	13
204	Does aspirin really reduce the risk of colon cancer?. <i>Lancet, The</i> , 2012 , 379, 1586-7; author reply 1587	4.0	7
203	Barrett's metaplasia glands are clonal, contain multiple stem cells and share a common squamous progenitor. <i>Gut</i> , 2012 , 61, 1380-9	19.2	60
202	Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke. <i>Nature Genetics</i> , 2012 , 44, 328-33	36.3	314
201	Aspirin and NSAIDs; benefits and harms for the gut. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2012 , 26, 197-206	2.5	21
200	Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. <i>European Journal of Cancer</i> , 2012 , 48, 2941-53	7.5	104
199	Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. <i>Nature Genetics</i> , 2012 , 44, 1341-8	36.3	681
198	Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. <i>Gastroenterology</i> , 2012 , 143, 336-46	13.3	305
197	Genome-wide association study implicates HLA-C*01:02 as a risk factor at the major histocompatibility complex locus in schizophrenia. <i>Biological Psychiatry</i> , 2012 , 72, 620-8	7.9	130
196	RHBDF2 mutations are associated with tylosis, a familial esophageal cancer syndrome. <i>American Journal of Human Genetics</i> , 2012 , 90, 340-6	11	127
195	Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. <i>Human Molecular Genetics</i> , 2012 , 21, 4996-5009	5.6	145
194	Common genetic determinants of intraocular pressure and primary open-angle glaucoma. <i>PLoS Genetics</i> , 2012 , 8, e1002611	6	131

193	Treatment of squamous cell and adenocarcinoma of the esophagus. <i>Gastrointestinal Cancer: Targets and Therapy</i> , 2012 , 39		
192	Conditional analysis identifies three novel major histocompatibility complex loci associated with psoriasis. <i>Human Molecular Genetics</i> , 2012 , 21, 5185-92	5.6	39
191	Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. <i>Nature Genetics</i> , 2012 , 44, 1131-6	36.3	139
190	The role of ATM in response to metformin treatment and activation of AMPK. <i>Nature Genetics</i> , 2012 , 44, 359-60	36.3	44
189	Aspirin chemoprevention in barrett esophagus: is the risk worth the benefit?. <i>Gastroenterology and Hepatology</i> , 2012 , 8, 831-3	0.7	
188	Why is there a change in patterns of GE cancer?. <i>Recent Results in Cancer Research</i> , 2012 , 196, 115-40	1.5	2
187	Chemoprevention in Barrett's esophagus: A pill a day?. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2011 , 21, 155-70	3.3	12
186	The clonal origins of dysplasia from intestinal metaplasia in the human stomach. <i>Gastroenterology</i> , 2011 , 140, 1251-1260.e1-6	13.3	64
185	Chemoprevention in Barrett's oesophagus. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2011 , 25, 569-79	2.5	12
184	Aspirin in the prevention of cancer. <i>Lancet, The</i> , 2011 , 377, 1649-50; author reply 1651-2	40	7
183	Gastroesophageal reflux disease and bulimia nervosa--a review of the literature. <i>Ecological Management and Restoration</i> , 2011 , 24, 79-85	3	22
182	Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. <i>Nature Genetics</i> , 2011 , 43, 117-20	36.3	319
181	Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. <i>Nature Genetics</i> , 2011 , 43, 761-7	36.3	646
180	Endoscopic therapies for the prevention and treatment of early esophageal neoplasia. <i>Expert Review of Gastroenterology and Hepatology</i> , 2011 , 5, 731-43	4.2	5
179	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. <i>Nature</i> , 2011 , 476, 214-9	50.4	1948
178	Guidelines for the management of oesophageal and gastric cancer. <i>Gut</i> , 2011 , 60, 1449-72	19.2	404
177	Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21. <i>Human Molecular Genetics</i> , 2011 , 20, 345-53	5.6	178
176	Acid reflux and oesophageal cancer. <i>Recent Results in Cancer Research</i> , 2011 , 185, 65-82	1.5	11

175	Cytoplasmic beta-catenin accumulation is a good prognostic marker in upper and lower gastrointestinal adenocarcinomas. <i>Histopathology</i> , 2010 , 57, 101-11	7.3	16
174	A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. <i>Nature Genetics</i> , 2010 , 42, 985-90	36.3	773
173	Long-term proton pump induced hypergastrinaemia does induce lineage-specific restitution but not clonal expansion in benign Barrett's oesophagus in vivo. <i>Gut</i> , 2010 , 59, 156-63	19.2	23
172	Surgery versus radical endotherapies for early cancer and high grade dysplasia in Barrett's oesophagus. <i>Cochrane Database of Systematic Reviews</i> , 2010 , CD007334		6
171	Diagnosis and management of Barrett's oesophagus. <i>BMJ, The</i> , 2010 , 341, c4551	5.9	43
170	Failure to validate association between 12p13 variants and ischemic stroke. <i>New England Journal of Medicine</i> , 2010 , 362, 1547-50	59.2	71
169	Clonality assessment and clonal ordering of individual neoplastic crypts shows polyclonality of colorectal adenomas. <i>Gastroenterology</i> , 2010 , 138, 1441-54, 1454.e1-7	13.3	104
168	PWE-065 Investigating clonal competition in Barrett's associated tumorigenesis using spatial maps of genetic heterogeneity. <i>Gut</i> , 2010 , 59, A111.1-A111	19.2	1
167	In vivo analysis of gut function and disease changes in a zebrafish larvae model of inflammatory bowel disease: a feasibility study. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 1162-72	4.5	66
166	Dissecting GI phenotype-genotype relationships in GERD and dyspepsia: an SNP here and an SNP there!. <i>American Journal of Gastroenterology</i> , 2009 , 104, 286-8	0.7	7
165	Laparoscopic fundoplication compared with medical management for gastro-oesophageal reflux disease: cost effectiveness study. <i>BMJ, The</i> , 2009 , 339, b2576	5.9	39
164	Prevention of colorectal cancer by combining early detection and chemoprevention. <i>Current Colorectal Cancer Reports</i> , 2009 , 5, 48-54	1	2
163	Analysis of the clonal architecture of the human small intestinal epithelium establishes a common stem cell for all lineages and reveals a mechanism for the fixation and spread of mutations. <i>Journal of Pathology</i> , 2009 , 217, 489-96	9.4	44
162	Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. <i>Nature Genetics</i> , 2009 , 41, 1330-4	36.3	411
161	Clonality, founder mutations, and field cancerization in human ulcerative colitis-associated neoplasia. <i>Gastroenterology</i> , 2009 , 136, 542-50.e6	13.3	139
160	Biomarkers in gastroenterology: between hope and hype comes histopathology. <i>American Journal of Gastroenterology</i> , 2009 , 104, 1093-6	0.7	49
159	Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. <i>Lancet Oncology, The</i> , 2009 , 10, 501-7	21.7	555
158	Aspirin in the primary prevention of vascular disease. <i>Lancet, The</i> , 2009 , 374, 877-8; author reply 879	40	1

157	Surgery versus radical endotherapies for early cancer and high grade dysplasia in Barrett's oesophagus. <i>Cochrane Database of Systematic Reviews</i> , 2009 , CD007334		7
156	Chemoprevention of oesophageal cancer and the AspECT trial. <i>Recent Results in Cancer Research</i> , 2009 , 181, 161-9	1.5	76
155	Physiological and molecular analysis of acid loading mechanisms in squamous and columnar-lined esophagus. <i>Ecological Management and Restoration</i> , 2008 , 21, 529-38	3	16
154	Faecal dimeric M2 pyruvate kinase in colorectal cancer and polyps correlates with tumour staging and surgical intervention. <i>Colorectal Disease</i> , 2008 , 10, 244-8	2.1	46
153	Mortality risks associated with Barrett's oesophagus: authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 27, 853-854	6.1	1
152	Mechanisms of field cancerization in the human stomach: the expansion and spread of mutated gastric stem cells. <i>Gastroenterology</i> , 2008 , 134, 500-10	13.3	198
151	Chemoprevention and Barrett's esophagus: decisions, decisions. <i>American Journal of Gastroenterology</i> , 2008 , 103, 2443-5	0.7	7
150	Management of Barrett's esophagus in the UK: overtreated and underbiopsied but improved by the introduction of a national randomized trial. <i>American Journal of Gastroenterology</i> , 2008 , 103, 1079-89	0.7	96
149	Genetics of gastroesophageal cancer: paradigms, paradoxes, and prognostic utility. <i>American Journal of Gastroenterology</i> , 2008 , 103, 443-9	0.7	32
148	Esophageal adenocarcinoma in "mice and men": back to basics!. <i>American Journal of Gastroenterology</i> , 2008 , 103, 2367-72	0.7	19
147	Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus. <i>Gut</i> , 2008 , 57, 1041-8	19.2	150
146	Cyclooxygenase-2 inhibitors in colorectal cancer prevention: counterpoint. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008 , 17, 1858-61	4	18
145	Ectopic expression of P-cadherin correlates with promoter hypomethylation early in colorectal carcinogenesis and enhanced intestinal crypt fission in vivo. <i>Cancer Research</i> , 2008 , 68, 7760-8	10.1	55
144	Minimal access surgery compared with medical management for chronic gastro-oesophageal reflux disease: UK collaborative randomised trial. <i>BMJ, The</i> , 2008 , 337, a2664	5.9	73
143	Mortality rates in patients with Barrett's oesophagus. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 27, 316-20	6.1	65
142	Cadherin switching dictates the biology of transitional cell carcinoma of the bladder: ex vivo and in vitro studies. <i>Journal of Pathology</i> , 2008 , 215, 184-94	9.4	43
141	Chemoprevention of gastrointestinal cancer. <i>British Journal of Surgery</i> , 2008 , 95, 674-6	5.3	2
140	The effect of alginates on deoxycholic-acid-induced changes in oesophageal mucosal biology at pH 4. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2007 , 18, 317-33	3.5	6

139	Hyperplastic polyps, serrated adenomas, and the serrated polyp neoplasia pathway. <i>Current Colorectal Cancer Reports</i> , 2007 , 3, 3-9	1	1
138	The evidence base of proton pump inhibitor chemopreventative agents in Barrett's esophagus--the good, the bad, and the flawed!. <i>American Journal of Gastroenterology</i> , 2007 , 102, 21-3	0.7	25
137	Detection of Intestinal Metaplasia in Barrett's Esophagus. <i>American Journal of Gastroenterology</i> , 2007 , 102, 2353-2354	0.7	1
136	Detection of intestinal metaplasia in Barrett's esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. <i>American Journal of Gastroenterology</i> , 2007 , 102, 1154-61	0.7	200
135	Corrigendum to: The effect of alginates on deoxycholic-acid-induced changes in oesophageal mucosal biology at pH 4. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2007 , 18, 939-939	3.5	
134	A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. <i>Clinical Cancer Research</i> , 2007 , 13, 5869-75	12.9	109
133	Molecular changes in the progression of Barrett's oesophagus. <i>Postgraduate Medical Journal</i> , 2007 , 83, 529-35	2	12
132	Chemoprevention of colorectal cancer. <i>Digestion</i> , 2007 , 76, 51-67	3.6	63
131	Adenocarcinoma in Barrett Esophagus. <i>Journal of Clinical Gastroenterology</i> , 2007 , 41, S129-S134	3	3
130	Barrett's Esophagus: Diagnosis, Screening, Surveillance, and Controversies. <i>Gut and Liver</i> , 2007 , 1, 93-100.	4.8	10
129	The Role of Drugs and Nutrition in the Prevention of Esophageal Adenocarcinoma Associated with Barrett's Esophagus 2007 , 17-31		
128	Genetics of inflammatory bowel disease and associated cancers. <i>Current Colorectal Cancer Reports</i> , 2006 , 2, 191-199	1	1
127	Clonal expansion in the human gut: mitochondrial DNA mutations show us the way. <i>Cell Cycle</i> , 2006 , 5, 808-11	4.7	37
126	Drinking from the fountain of promise: biomarkers in the surveillance of Barrett's oesophagus--the glass is half full!. <i>Gut</i> , 2006 , 55, 1377-9	19.2	11
125	A methodologic analysis of chemoprevention and cancer prevention strategies for gastrointestinal cancer. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2006 , 3, 101-11		24
124	Mitochondrial DNA mutations are established in human colonic stem cells, and mutated clones expand by crypt fission. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 714-9	11.5	234
123	Met receptor signaling: a key effector in esophageal adenocarcinoma. <i>Clinical Cancer Research</i> , 2006 , 12, 5936-43	12.9	31
122	Mechanisms of disease: from stem cells to colorectal cancer. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2006 , 3, 267-74		63

121	The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. <i>Gastroenterology</i> , 2006 , 131, 1392-9	13.3	767
120	NSAID and oesophageal adenocarcinoma: randomised trials needed to correct for bias. <i>Lancet Oncology</i> , 2006 , 7, 7-8; author reply 8-9	21.7	5
119	Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. <i>Clinical Cancer Research</i> , 2006 , 12, 4283-7	12.9	142
118	Molecular biology of Barrett's cancer. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , 2006 , 20, 813-27	2.5	27
117	Improving surveillance for Barrett's oesophagus: AspECT and BOSS trials provide an evidence base. <i>BMJ</i> , 2006 , 332, 1512	5.9	40
116	Cancer prevention. <i>BMJ</i> , 2005 , 331, 618	5.9	1
115	Molecular pathways in bladder cancer: part 1. <i>BJU International</i> , 2005 , 95, 485-90	5.6	30
114	Molecular pathways in bladder cancer: part 2. <i>BJU International</i> , 2005 , 95, 491-6	5.6	23
113	Premalignant Lesions of the Oesophagus: Identification to Management 2005 , 259-269		1
112	A family history of Barrett's oesophagus: another risk factor?. <i>Scandinavian Journal of Gastroenterology</i> , 2005 , 40, 1127-8	2.4	19
111	An antiapoptotic role for gastrin and the gastrin/CCK-2 receptor in Barrett's esophagus. <i>Cancer Research</i> , 2004 , 64, 1915-9	10.1	75
110	Acid suppression and chemoprevention in Barrett's oesophagus. <i>Digestive Diseases</i> , 2004 , 22, 171-80	3.2	16
109	The metabolic marker tumour pyruvate kinase type M2 (tumour M2-PK) shows increased expression along the metaplasia-dysplasia-adenocarcinoma sequence in Barrett's oesophagus. <i>Journal of Clinical Pathology</i> , 2004 , 57, 1156-9	3.9	25
108	Re: Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. <i>Journal of the National Cancer Institute</i> , 2004 , 96, 885-7; author reply 887	9.7	43
107	Review article: management of oesophageal adenocarcinoma -- control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus. <i>Alimentary Pharmacology and Therapeutics</i> , 2004 , 20 Suppl 5, 71-80; discussion 95-6	6.1	33
106	Review article: approaches to Barrett's oesophagus treatment-the role of proton pump inhibitors and other interventions. <i>Alimentary Pharmacology and Therapeutics</i> , 2004 , 19 Suppl 1, 54-9	6.1	16
105	A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. <i>Gastroenterology</i> , 2004 , 127, 310-30	13.3	521
104	Phase II trial of gefitinib (ZD1839) in advanced adenocarcinoma of the oesophagus incorporating biopsy before and after gefitinib. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4021-4021	2.2	14

103	Phase II trial of gefitinib (ZD1839) in advanced adenocarcinoma of the oesophagus incorporating biopsy before and after gefitinib. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4021-4021	2.2	6
102	Upregulation of the oncogene c-myc in Barrett's adenocarcinoma: induction of c-myc by acidified bile acid in vitro. <i>Gut</i> , 2003 , 52, 174-80	19.2	113
101	Commentary: The relation of obesity, reflux and its implications. <i>International Journal of Epidemiology</i> , 2003 , 32, 650-1	7.8	1
100	Gastro-esophageal reflux disease and bile acids. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2003 , 36, 172-4	2.8	5
99	Barrett's esophagus: environmental influences in the progression of dysplasia. <i>World Journal of Surgery</i> , 2003 , 27, 1014-7	3.3	8
98	Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor. <i>Gastroenterology</i> , 2003 , 124, 615-25	13.3	131
97	The role of receptor tyrosine kinase inhibition in treating gastrointestinal malignancy. <i>Expert Opinion on Investigational Drugs</i> , 2003 , 12, 577-92	5.9	1
96	Transient P-cadherin expression in radiation proctitis; a model of mucosal injury and repair. <i>Journal of Pathology</i> , 2002 , 197, 194-200	9.4	12
95	Contribution of cyclin d1 (CCND1) and E-cadherin (CDH1) polymorphisms to familial and sporadic colorectal cancer. <i>Oncogene</i> , 2002 , 21, 1928-33	9.2	80
94	Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action. <i>Oncogene</i> , 2002 , 21, 6071-81	9.2	159
93	Aberrant P-cadherin expression is an early event in hyperplastic and dysplastic transformation in the colon. <i>Gut</i> , 2002 , 50, 513-9	19.2	48
92	Curing oesophageal cancer: one swallow does not make a summer. <i>European Journal of Gastroenterology and Hepatology</i> , 2002 , 14, 1173-5	2.2	2
91	10-minute consultation: Gastro-oesophageal reflux disease. <i>BMJ, The</i> , 2002 , 325, 945	5.9	2
90	Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west. <i>Gastroenterology</i> , 2002 , 122, 588-90	13.3	108
89	Superficial Esophageal Cancer: Adenocarcinoma Related to Barrett's Metaplasia and Adenoid Cystic Carcinoma 2002 , 169-180		
88	Gastroenterology. <i>BMJ, The</i> , 2002 , 325, S113	5.9	
87	Down-regulation of E-cadherin and E-catenin in Helicobacter pylori Associated Gastritis and Gastric Carcinoma: An Immunohistochemical Study 2002 , 4, 203-208		2
86	The continuing tale of cytokeratins in Barrett's mucosa: as you like it. <i>Gut</i> , 2001 , 49, 746-7	19.2	7

85	Effect of ectopic expression of rat trefoil factor family 3 (intestinal trefoil factor) in the jejunum of transgenic mice. <i>Journal of Biological Chemistry</i> , 2001 , 276, 24088-96	5.4	40
84	Squamous carcinoma of the oesophagus: continuing to challenge. <i>Digestive and Liver Disease</i> , 2001 , 33, 528-30	3.3	
83	The treatment, management and prevention of oesophageal cancer. <i>Expert Opinion on Biological Therapy</i> , 2001 , 1, 1017-28	5.4	9
82	Aberrant P-cadherin expression is a feature of clonal expansion in the gastrointestinal tract associated with repair and neoplasia. <i>Journal of Pathology</i> , 2000 , 190, 526-30	9.4	28
81	ABC of colorectal cancer. Molecular basis for risk factors. <i>BMJ: British Medical Journal</i> , 2000 , 321, 886-9		71
80	Barrett's esophagus: dysregulation of cell cycling and intercellular adhesion in the metaplasia-dysplasia-carcinoma sequence. <i>Digestion</i> , 2000 , 61, 1-5	3.6	25
79	Barrett's metaplasia. <i>Lancet, The</i> , 2000 , 356, 2079-85	4.0	288
78	Cadherin adhesion in the intestinal crypt regulates morphogenesis, mitogenesis, motogenesis, and metaplasia formation. <i>Journal of Clinical Pathology</i> , 1999 , 52, 166-8		7
77	Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. <i>Human Molecular Genetics</i> , 1999 , 8, 607-10	5.6	271
76	Barrett's esophagus: an overview of the molecular biology. <i>Ecological Management and Restoration</i> , 1999 , 12, 177-80	3	26
75	Apoptotic and proliferative activity in the neoplastic progression of Barrett's oesophagus: a comparative study. <i>Journal of Pathology</i> , 1999 , 187, 535-40	9.4	62
74	Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. <i>American Journal of Pathology</i> , 1999 , 154, 965-73	5.8	347
73	A colorectal cell line with alterations in E-cadherin and epithelial biology may be an in vitro model of colitis. <i>Journal of Clinical Pathology</i> , 1999 , 52, 231-42		4
72	Alterations in cadherin and catenin expression during the biological progression of melanocytic tumours. <i>Journal of Clinical Pathology</i> , 1999 , 52, 151-7		95
71	Sequential changes in cadherin-catenin expression associated with the progression and heterogeneity of primary oesophageal squamous carcinoma. <i>International Journal of Cancer</i> , 1998 , 79, 573-9	7.5	38
70	Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation. <i>American Journal of Pathology</i> , 1998 , 152, 135-44	5.8	134
69	Sequential changes in cadherin-catenin expression associated with the progression and heterogeneity of primary oesophageal squamous carcinoma 1998 , 79, 573		1
68	Changes in gene structure and regulation of E-cadherin during epithelial development, differentiation, and disease. <i>Progress in Molecular Biology and Translational Science</i> , 1997 , 57, 187-215		24

67	Growth factors: potential for the management of solid epithelial tumours. <i>Baillieres Clinical Gastroenterology</i> , 1996 , 10, 165-79		
66	Expression of transforming growth factor alpha, epidermal growth factor receptor and epidermal growth factor in precursor lesions to gastric carcinoma. <i>British Journal of Cancer</i> , 1995 , 71, 30-6	8.7	51
65	Molecular surveillance of Barrett's esophagus and putative strategies for genetic therapy. <i>Ecological Management and Restoration</i> , 1995 , 8, 113-118	3	2
64	Morphological analysis of gastro-esophageal diseases by molecular cell techniques. <i>Microscopy Research and Technique</i> , 1995 , 31, 184-92	2.8	3
63	Association of transforming growth factor alpha (TGFA) and its precursors with malignant change in Barrett's epithelium: biological and clinical variables. <i>International Journal of Cancer</i> , 1995 , 60, 27-32	7.5	58
62	Differential expression of e-cadherin in normal, metaplastic and dysplastic esophageal mucosa - a putative biomarker. <i>International Journal of Oncology</i> , 1994 , 4, 441-8	1	10
61	Maintenance of normal intestinal mucosa: function, structure, and adaptation. <i>Gut</i> , 1994 , 35, S1-4	19.2	28
60	Secretory and absorptive activity of oesophageal epithelium: evidence of circulating mucosubstances. <i>The Histochemical Journal</i> , 1994 , 26, 41-49		7
59	Expression of the trefoil peptides pS2 and human spasmodic polypeptide (hSP) in Barrett's metaplasia and the native oesophageal epithelium: delineation of epithelial phenotype. <i>Journal of Pathology</i> , 1994 , 173, 213-9	9.4	41
58	Cell cycle abnormalities in Barrett's esophagus: further insights. <i>Gastroenterology</i> , 1994 , 106, 553	13.3	1
57	Altered gene expression of growth factors and their receptors during esophageal tumorigenesis. <i>Gastroenterologie Clinique Et Biologique</i> , 1994 , 18, D40-5		7
56	Growth factors and oncogenes in Barrett's oesophagus and gastric metaplasia. <i>Endoscopy</i> , 1993 , 25, 637-41	3.4	23
55	The administration of supplementary oxygen to prevent hypoxia during upper alimentary endoscopy. <i>Endoscopy</i> , 1993 , 25, 269-73	3.4	27
54	Gene expression in Barrett's mucosa: acute and chronic adaptive responses in the oesophagus. <i>Gut</i> , 1993 , 34, 1649-50	19.2	32
53	Molecular events in Barrett's metaplasia. <i>Gastroenterology</i> , 1993 , 104, 1235-6	13.3	4
52	Oesophageal carcinoma. <i>European Journal of Cancer Prevention</i> , 1993 , 2, 5-12	2	4
51	Screening for alimentary cancer: outstanding problems and a new strategy for research. <i>European Journal of Cancer Prevention</i> , 1993 , 2, 211-4	2	1
50	Development and growth of normal; metaplastic and dysplastic oesophageal mucosa. <i>European Journal of Gastroenterology and Hepatology</i> , 1993 , 5, 235-246	2.2	10

49	Expression of epidermal growth factor, transforming growth factor alpha and their receptor in gastro-oesophageal diseases. <i>Digestive Diseases</i> , 1993 , 11, 1-11	3.2	45
48	Increased expression of epidermal growth factor receptors in Barrett's esophagus associated with alkaline reflux: a putative model for carcinogenesis. <i>American Journal of Gastroenterology</i> , 1993 , 88, 402-8	9.7	29
47	Hyperplastic polyps: a cell lineage which both synthesizes and secretes trefoil-peptides and has phenotypic similarity with the ulcer-associated cell lineage. <i>American Journal of Pathology</i> , 1993 , 142, 663-8	5.8	28
46	Role of salivary epidermal growth factor in the pathogenesis of Barrett's columnar lined oesophagus. <i>British Journal of Surgery</i> , 1992 , 79, 716	5.3	
45	Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus. <i>Gut</i> , 1992 , 33, 1033-8	19.2	112
44	Adenocarcinoma and Barrett's oesophagus. <i>Gut</i> , 1992 , 33, 862-3	19.2	
43	Transforming growth factor alpha in epithelial proliferative diseases of the breast. <i>Journal of Clinical Pathology</i> , 1992 , 45, 513-6	3.9	22
42	Epidermal growth factor in the oesophagus. <i>Gut</i> , 1992 , 33, 1448-53	19.2	45
41	Epidermal growth factor receptors in the oesophagus. <i>Gut</i> , 1992 , 33, 439-43	19.2	56
40	Proliferating cell nuclear antigen in oesophageal diseases; correlation with transforming growth factor alpha expression. <i>Gut</i> , 1992 , 33, 587-91	19.2	54
39	Behçet's syndrome in Scotland. <i>Postgraduate Medical Journal</i> , 1992 , 68, 566-70	2	46
38	Growth regulatory peptides in gastric mucosa. <i>Clinical Science</i> , 1992 , 82, 581-7	6.5	20
37	Glucose-6-phosphatase in normal adult human intestinal mucosa. <i>Clinical Science</i> , 1992 , 83, 683-7	6.5	10
36	Flow-cytometric assessment of regulatory peptides in Barrett's mucosa. <i>Gastroenterology</i> , 1992 , 103, 1121	13.3	2
35	Flow-cytometric analysis of growth-regulatory peptides and their receptors in Barrett's oesophagus and oesophageal adenocarcinoma. <i>Scandinavian Journal of Gastroenterology</i> , 1992 , 27, 147-54	2.4	46
34	Flow cytometry of oesophageal mucosal biopsies; epidermal growth factor receptor, and CD15. <i>Journal of Pathology</i> , 1992 , 167, 321-6	9.4	8
33	Epithelial stem cells in gastrointestinal morphogenesis, adaptation and carcinogenesis. <i>Seminars in Cell Biology</i> , 1992 , 3, 445-56		14
32	Helicobacter pylori infection and gastric cancer. <i>BMJ: British Medical Journal</i> , 1991 , 302, 1534		7

- 31 Epidermal Growth Factor in the Oesophagus. *Clinical Science*, **1991**, 80, 6P-6P
- 30 Abnormal expression of growth regulatory factors in Barrett's oesophagus. *Clinical Science*, **1991**, 81, 663-8 6.5 71
- 29 Cardiorespiratory effects during gastrointestinal endoscopy. *Anaesthesia*, **1991**, 46, 698 6.6 2
- 28 Uptake of horseradish peroxidase by human oesophageal explants over 24 h. *The Histochemical Journal*, **1991**, 23, 409-14 8
- 27 Evidence for hypomotility in non-ulcer dyspepsia: a prospective multifactorial study. *Gut*, **1991**, 32, 246-51 128
- 26 Self-assessment of medical knowledge: do physicians overestimate or underestimate?. *Journal of the Royal College of Physicians of London*, **1991**, 25, 306-8 7
- 25 Liver transplantation in patients with alcoholic cirrhosis. *BMJ: British Medical Journal*, **1990**, 301, 390 2
- 24 Improved silver staining of nucleolar organiser regions in paraffin wax sections using an inverted incubation technique. *Journal of Clinical Pathology*, **1990**, 43, 1029-31 3.9 10
- 23 Hypercalcaemia in rheumatoid arthritis revisited. *Annals of the Rheumatic Diseases*, **1990**, 49, 22-4 2.4 7
- 22 Changes in keratan sulphate levels in the serum of a long distance runner. *Rheumatology*, **1990**, 29, 314-5 1
- 21 Neuroendocrine Tumors 564-668
- 20 Epidemiology of Hepatocellular Carcinoma 409-420
- 19 Chemoprevention for Barrett's Esophagus 236-252
- 18 Preventing GI Cancer in those at Risk 156-167
- 17 Epidemiology of Gastroesophageal Cancer 1-13
- 16 Rare Tumors of the Abdomen 259-289
- 15 Cancer of the Colon and Rectum 325-373
- 14 Factors Involved in Carcinogenesis and Prevention in Hepatobiliary Cancer 421-432

13 Molecular Biology of Hepatobiliary Cancer433-440

12 Primary Liver Cancer441-468

11 Metastatic Liver Cancer469-497

10 Primary Pancreatic Adenocarcinoma498-542

9 Rare Tumors of the Liver669-687

8 Cystic Neoplasms of the Pancreas688-710

7 Molecular Biology of Gastroesophageal Cancers: The Role of Mutational Analysis in Prognosis21-30

6 Esophageal Adenocarcinoma31-113

5 Squamous Cancer of the Esophagus114-145

4 Diffuse Gastric Cancer146-176

3 Intestinal Gastric Cancer177-188

2 Small Bowel Tumors189-226

1 Sarcoma and Gastrointestinal Stromal Tumors227-258